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Introduction
This overview will consider the relationship between
hypertension and peripheral arterial disease (PAD). The
following issues will be discussed : how is hypertension
a promoter of PAD, what are the characteristics of
hypertension in such patients, what is the benefit after
treating hypertension, what is the optimal blood pressure
target and what is the strategy to reach such goal ? 
Epidemiology of the relationship between hyperten-
sion and peripheral arterial disease (PAD)
Atherosclerosis is a systemic vascular disease. It is thus
not surprising that there is a frequent coexistence in the
adult population of CAD (coronary arterial disease),
PAD and cerebral vascular accident (CVA). By classical
definition, PAD is a condition in which atherosclerotic
lesions of the lower limbs provoke symptoms of claudi-
cation, ischaemic pain or trophic lesions in the legs.
ARONOW et al. (1) observed in such patients older than
62 years that CAD was present in 21%, CVA in 9% and
PAD in 8% but 5% of this population presented simulta-
neously the 3 complications with an associated huge
increased cardiovascular mortality.
The presence of PAD with intermittent claudication is
commonly associated with CV risk factors. Among the
modifiable ones, diabetes confers a risk for developing
PAD X 2. For smoking, the odds ratio is X 2,5. For HTA
and hypercholesterolaemia it is X 1.5 (Table 1) (2)
Moreover, these factors are frequently aggregated in the
same patient, increasing so the cardiovascular risk in a
very large proportion. From the Framingham study,
KANNEL (3) observed (either in men or women) that 50%
of the hypertensive patients presented 1 or 2 added risk
factors, 20% 3 risk factors and only less than 20% of the
studied US population had isolated high blood pressure.
This observation is rather the same in all the industrial-
ized populations. MURABITO et al. (4) studying the
Framingham offspring population (1554 males and
1759 females with mean age of 59 years examined
between 1995 and 1998), noted that odds ratio for
significant associations between PAD (identified by
ankle-brachial pressure index < 0.9) and HTA from
multivariate analysis was 2.2.
Atherosclerosis is first the result of endothelial dys-
function secondary to oxidative stress. Such a stress is
due to several factors injuring the endothelial wall. High
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Abstract. Arterial hypertension (HTA) is a promoter of peripheral arterial disease (PAD) in association with other
atherosclerotic risk factors. Systolic HTA is the most frequently noted form in such disease, secondary to marked
increase in large artery stiffness.
The existence of PAD confers on the hypertensive patient a very high cardiovascular (CV) risk, requiring an intensive
global therapeutical approach. Treating HTA is one of such beneficial actions. The optimal blood pressure (BP) to be
reached is at least < 140/90 mmHg but lower BP should be targeted if possible ( 130/80 mmHg). First of all, a
modification of the lifestyle and diet should be proposed. But to reach such a low target, different antihypertensive
agents must be very often used in association. The inhibitors of the renin-angiotensin system constitute one of the main
axis of such drug treatment, after having avoided the pitfall of renal artery stenosis.
Table 1








Male sex  2.5
Age (per 10 y)  2
Adapted from the Prevention of Atherothrombotic Disease
Network, Arch Intern Med, 2003, 163 : 884-92.
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BP leads to increased shear stress creating endothelial
damage and dysfunction.
For KANNEL (5), hypertensive male patients presented
a PAD 2 times more frequently and this disease was even
noted 3 times more frequently in women as compared to
normotensives. Moreover, PAD was associated with
considerable morbidity and mortality from CV causes,
with an annual mortality of 25% when critical leg
ischaemia (5).
Importance of the ankle-brachial pressure index
(ABP)
When screening individuals for their cardiovascular risk,
determination of the ankle-brachial pressure index
(ABPI) has been proposed as a sensitive measure to
detect PAD, the existence of which is characterized by a
low value of this ABPI. Such situation has also been
associated with increased CV morbidity and mortali-
ty (7).
In the most recent years, an important epidemiologi-
cal aspect in CV risk was considered due to the epidem-
ic obesity frequently associated to the metabolic syn-
drome. The definition of the later has been reviewed by
several associations such as the NCEP ATP III (National
Cholesterol Education Program-ATP III) (8-9) or the
European Group for the study of Insulin Resistance
(EGIR) (10).
For the American guidelines, such diagnosis is estab-
lished when at least 3 of the following risk criteria are
met : blood glucose  110 mg/dl (6.1 mmol/l), waist
circumference  102 cm in men,  88 cm in women,
HDL cholesterol lower than 40 mg/dl (1 mmol/l) in men
and less than 50 mg/dl (1.3 mmol/l) in women, triglyc-
erides  150 mg/dl (1.7 mmol/l) and a BP higher than
130/85 mmHg.
For the European guidelines (11), these criteria have
been a bit different : a waist circumference  94 cm in
men,  80 cm in women, a BP > 140/90 mmHg in
both sex, a blood glucose > 110 mg/dl, triglycerides
> 150 mg/dl and a HDL cholesterol < 40 mg/dl in men
as in women. 
Considering this problem of metabolic syndrome,
OLIJHOEK et al. (12) studied in the same time these meta-
bolic syndrome components and potential existence of a
low ABPI (Table 2). These authors observed that only
2% of the population presented a low ABPI ( 0.9) in at
least one leg when no metabolic syndrome component
was present. This percentage, however, increased to
12% when 3 components were noted and to 22% when
all the 5 components were present. The prevalence of
microalbuminuria increased also in parallel with the
number of metabolic syndrome components. In this
order of idea, the components of the metabolic syn-
drome are frequently noted in chronic kidney disease
(CKD) (13) and CKD could also be caused by such syn-
drome. For its part, CKD is frequently associated to
PAD (14).
Recently, it was observed that subclinical PAD,
detected by a ABPI less than or equal to 0.9, was com-
mon (32%) in non dialysed patients with CKD, related
to age, male sex and a more severe degree of renal in-
sufficiency (15). In this study, however only 30% yet
presented a clinical picture compatible with intermittent
claudication.
Characteristics of the hypertension in PAD patients
A strong association has been more often demonstrated
between elevated systolic BP (than the diastolic compo-
nent) and intermittent claudication. 
GAGNON et al. (16) studied more than 4000 men aged
35-64 years who did not suffer from PAD at the begin-
ning period of a follow-up of 16 years. For those indi-
viduals in the highest quintile of SBP (> 152 mmHg),
the RR was found to be 2.7 to develop intermittent clau-
dication, but for those in the highest quintile for DBP
(> 92 mmHg), the RR was only 1.5. 
In the same order of idea, VOGT et al. (17) evaluated
575 patients with unisegmental PAD, 587 with multi
segmental disease and 243 patients without apparent dis-
ease. Elevated SBP was found to be a key risk factor for
arterial disease at a proximal level : isolated aortic, iliac
and femoropopliteal arterial disease, in both men and
women. For distal arterial disease, in women, elevated
SBP was also the major correlate, while in men, the main
correlate was especially an history of diabetes mellitus.
The explanation for increasing more the systolic
component of BP is the following :
In PAD, when the central aortic pressure waveforms
are recorded, derived from percutaneous tonometry
tracings, as conduit arteries are stiffening, the second
Table 2
Components of the metabolic syndrome in relation to
decreased ABPI








Decreased ABPI : Ankle Brachial Pressure Index  0.90 in at least
one leg (age- and sex adjusted).
* Patients with clinical symptomatic PAD were excluded from
analyses.
Adapted from OLIJHOEK J. et al. Eur Heart J, 2004.
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systolic peak becomes more prominent due to increase
in pulse wave velocity (PWV) and earlier pulse wave
reflection. Therefore, the energy of the reflected wave
will combine at an earlier time with the antegrade pulse
wave, thus increasing the augmentation index. This
parameter is influenced by the reflective properties of
the arterial system and is strongly dependent on PWV
and the travelling distance of pressure waves (body
height).
The SBP increases as a result of this abnormality and
the DBP decreases at the same time. Thus, pulse pres-
sure is generally high in PAD and such abnormality is of
importance when CV risk is considered. Indeed, SAFAR
et al. (18) analysing data from 3 important studies in
systolic HTA treating old patients (EWPHE, SYSTEUR
and SYST CHINA) observed that the CV risk increased
with the SBP level but for each level considered, the risk
was higher when the pulse pressure was higher.
In the SHEP trial (systolic HTA in the elderly pro-
gram), the prevalence of lower extremity arterial disease
was assessed in a population of hypertensive patients
older than 60 years and with SBP > 160 mmHg (19).
Using the criteria of clinical symptoms of intermittent
claudication, a prevalence of 6.5% was observed, but
using the criterion of an ABPI  0.9, this prevalence
reached 26.7% linked to age, smoking and low HDL
cholesterol.
In this SHEP study, and for a mean follow-up of 16
months, NEWMAN et al. (20) noted that mortality and
morbidity were higher in 1537 patients with systolic
HTA and low ABPI as compared to patients with ABPI
higher than 0.9 : for total deaths, the RR adjusted for age
and sex was 3.8, for the CHD deaths this risk was
increased by 3.2 and for CVD deaths, the RR was
increased by 3.7 in the low ABPI group.
Is treating HTA beneficial in such PAD patients ?
The answer is of course positive. Treating HTA in high
CV risk is very useful and profitable from a pharmaco-
economic point of view. But, the beneficial effects of
treating HTA on atherosclerosis disease or on CV events
have not been directly evaluated in patients presenting
both PAD and HTA and this is also the case for PAD and
diabetes. However, observational data and those derived
from trials in people with other manifestations of CV
disease may be probably generalized to support the
importance of treating key risk factors such as HTA in
PAD.
Indeed, the large intervention for treating HTA trials
have not specifically targeted patients with PAD. In the
absence of such data, consensus still supports the man-
agement of HTA in these patients as PAD is included in
the group of markers of CV disease and calls for mainte-
nance of BP level less than 130-80 in these patients (21). 
According to the recent ESH-ESC Guidelines (11), in
stage 1 HTA with additional CV disease risk factors,
achieving a sustained 12 mmHg reduction in SBP over
10 years will prevent 1 death for every 11 patients treat-
ed. However, in the detailing of the parameters defining
target organ damage (TOD) and/or associated clinical
complications linked to the BP risk evaluation, these
new guidelines have included the presence of PAD
either symptomatic or detected by the presence of
plaques or even by a ABPI  0.9. The existence of TOD
or associated clinical conditions (ACC) with a BP mea-
sured in the range of the high normal BP group (130-
139/85-89 mmHg) gives a high added or even a very
high added risk to the patient and this position could be
an argument to decide very quickly initiation of antihy-
pertensive agent prescription.
In the JNC 7 even, CHOBANIAN et al. (22) considered
PAD equivalent in risk to ischaemic heart disease.
What is the optimal BP target and how to reach it ?
The goals for treatment of HTA in PAD patients are to
reduce CVD and renal morbidity and mortality. 
In patients suffering from diabetes or CKD, the target
BP should be < 130/80 mmHg.
In patients with a high CV risk such as the patients
with PAD, this threshold could be proposed : however, a
too large and rapid reduction of BP could worsen inter-
mittent claudication and perhaps unmask a coronary
heart disease, frequently associated. This can be the case
whatever drug treatment used and no evidence exists
that beta-blockers are particularly more culpable in this
problem of aggravating leg symptoms.
In type 2 diabetes, MEHLER et al. (23) noted that inten-
sive control BP reduced more the risk of CV events
when PAD was present. They compared a moderate
target BP under treatment (BP < 140/85 mmHg) and an
intensive target (BP < 130/80 mmHg) dividing their
population according to the baseline ABPI. After adjust-
ing for age, sex, duration of diabetes, smoking habits,
total cholesterol level, history of myocardial infarction
or stroke, and adjusted cornell voltage, patients random-
ized to moderate treatment had an inverse relationship
between ABPI and events (p = 0.009). On the other
hand, patients intensively treated (with nisoldipine or
enalapril in this study) had no such relationship between
ABPI and events, demonstrating the protective effects of
intensive BP treatment in such high CV risk patients.
What treatment should be proposed first ?
1. The non-pharmacological approach has a central
role in treating HTA in such patients presenting PAD.
Measures affecting the lifestyle have indeed a role in BP
reduction but also, for several approaches, an added
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useful coronary protection profile (Table 3). For the BP
reduction, weight control and salt restriction are the
most powerful, but for coronary protection (and diffuse
arterial), mediterranean diet, dietary fish, omega 3 con-
sumption and stopping smoking have the most important
effect. However, moderate exercise and weight control
associated with a moderate alcohol intake offer a pro-
tective and interesting effect on the coronary events.
Concerning salt intake, GATES et al. (24) noted that sodi-
um restriction rapidly improves large elastic arterial
compliance in older adults with systolic HTA, this para-
meter being particularly decreased in PAD.
2. In JNC 7, any class of antihypertensive drugs
could be used in most patients with PAD (22). Besides
the important non-pharmacological approach, the algo-
rithm for treatment of HTA, when PAD exists, insists on
introducing antihypertensive drugs when the BP was not
yet in the normal range (Fig. 1). The preferred initial
drug choice could be one drug at its full dosage or a two
drugs combination at a lower dosage. After several
weeks, if the patient is not yet at the goal BP, an opti-
mization of the dosages or adding a third drug has to be
proposed until goal BP is achieved. However, BP should
decrease slowly in these patients. In paralell, other risk
factors must also be managed aggressively, such as by
statine and aspirin prescriptions. In the UKPDS (United
Kingdom Prospective Diabetes Study) performed in
type 2 diabetes, if diabetes end-points and risks of stroke
were significantly reduced by tight BP, risk for myocar-
dial infarction or for amputation related to PAD were not
significantly reduced (24).
Table 3




Weight control +++ ++
Salt restriction ++ ?
Moderate exercise ++ ++
Mediterranean diet + +++
Dietary fish ± +++
Stopping smoking – +++
Fig. 1
Algorithm for Treatment of Hypertension when PAD coexists
Adapted from The sixth report of the Joint National Committee Arch Intern Med, 1997, 157 : 2413-45.
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Is there an ideal antihypertensive drug with addi-
tional properties ?
The different antihypertensive classes are possible can-
didates for treating high BP in PAD population.
Beta-blockers (BB) are known to reduce mean BP,
cardiac output and blood flow in the peripheral circula-
tion including exercising muscles, due to blockade of the
vascular ß2 receptors. Non-selective BB could thus
worsen the symptoms of PAD. However, BOGAERT &
CLEMENT (26) were unable to observe any influence of
beta-blockers on walking distance in patients with
chronic intermittent claudication, comparing
propanolol, metoprolol and placebo.
SOLOMON et al. (27) found neither adverse nor benefi-
cial effects with atenolol, a cardioselective ß1 BB as
compared to the calcium channel antagonist nifedipine
on PAD when given as a single therapy. However, the
combination of both decreased walking ability by 9%.
But we must be cautious not to apply such a BB treat-
ment to too severely affected PAD patients. Newer BB
with vasodilating properties could yet be more benefi-
cial. This theoretical advantage however deserves
prospective studies.
Angiotensin converting enzyme inhibitors (ACEI)
may constitute an excellent choice for antihypertensive
therapy in patients with PAD, particularly when some
collateral flows exist. HIRSCH & DUPREZ (28) reviewed
the interest of ACEI treatment in PAD and concluded
that such therapy could improve clinical symptoms in
PAD. For instance, ACEI can also improve arterial com-
pliance of the large arteries leading to a decreased in the
cardiac work. However, attention should also be paid to
renal function in the case of coexistence of renal artery
stenosis (RAS) which can frequently enough occur in
such patients. In this context, it must be remembered
that lower limb occlusion disease was noted in 20 to
40% of patients suffering from RAS  50% (29-30).
In the HOPE trial (Heart Outcomes Prevention
Evaluation study) (31), from a total of 9297 patients,
4051 suffered from PAD. The high dosage of ramipril
(10 mg) was particularly useful in protecting such high
CV risk patients with PAD. This treatment reduced CV
morbidity and mortality by around 25% more than in the
placebo group. Patients did not have to be hypertensive
to be included in this study, and the observed risk reduc-
tion could not be accounted for by the relatively modest
reduction of BP. The implication of the HOPE study is
that most patients with PAD would benefit from an
ACEI, provided that treatment is not associated with a
deterioration of renal function due to occult RAS.
In the VALUE study (32), 14% presented PAD and all
of these patients had high CV risk. In this trial, the cal-
cium channel blocker (CCB) amlodipine was, during the
first months of the study, more beneficial for the CV
protection than the angiotensin II receptor blocker
(ARB), valsartan, probably due to a more rapid and
prominent antihypertensive effect, and this was particu-
larly noted for the problem of myocardial infarction
complications.
As summarized in a recent review (28), ACEI were
remembered to provide vascular protective effects such
as improvement of endothelial dysfunction, BP lowering
and promotion of angiogenesis in ischaemic lesion. At
the clinical point of view, they increase the ABPI, the
peripheral blood flow (demonstrated in small scale clin-
ical investigations) and decrease morbidity and mortali-
ty (proven in large-scale prospective investigations such
as HOPE or EUROPA for European trial On reduction
of cardiac events with Perindopril in stable coronary
Artery disease investigators) (33). In this later large
study, ACEI perindopril at high dosage among patients
with stable coronary heart disease without heart failure
significantly improved outcomes. In this study, 7% of
the population suffered from PAD.
In the LIFE study (Losartan Intervention For
Endpoint reduction in hypertension study) (34), the ARB
losartan was also found to significantly reduce the com-
posite endpoint of CV death, myocardial infarction or
stroke in patients with hypertension and LVH compared
with atenolol. Although the results seem to be very com-
parable to the HOPE data, when analysing the prevalence
of coronary or peripheral revascularization procedures, a
pre-specified secondary endpoint, no difference was
found between the 2 treatment groups. The total number
of participants with a history of PAD included in the
LIFE study was much lower than in the HOPE trial (6%
or 8.5% when considering only systolic HTA) (35).
However, the use of losartan for the treatment of HTA in
patients with PAD can be recommended but possible
additional protective vascular effects of losartan and
other ARB on PAD are still to be determined.
Thus, in theory and to summarize, all the 6 classes of
drugs could be a first optimal choice, but ACEI and ARB
could be prefered if no RAS is suspected. Calcium chan-
nel blocker could be another excellent option when RAS
is suspected.
ß1 selective BB or non selective BB with additive
vasodilating properties could also be useful if a coronary
problem but no critical leg ischaemia is present. 
However, very often, association of several antihy-
pertensive agents are necessary to reach the target sys-
tolic BP in such PAD patients with alteration of large
arteries and systolic HTA.
Diuretics could also be used but at a low dosage.
Indeed, ERKENS et al. (36) noted that the thiazide diuret-
ic use was associated with excess amputations. Thus we
must keep in mind this and be cautious when using high
dosage of such diuretic treatment in PAD with HTA and
diabetes mellitus.
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Conclusion
The definition of PAD is equivalent in risk to ischaemic
heart disease as recently considered by the JNC
7 report (22). Systolic HTA is frequently noted in such
patients with vascular alteration, due to arterial stiffness.
To reduce the CV risk, BP must be treated when higher
than 140/90 mmHg first by a non-pharmacological
approach. If the BP is not yet reduced to the target
(which ideally could be less than 130/80 mmHg), a drug
therapy must be started.
Any class of antihypertensive drugs can be used but a
preferential option should be ACEI (or ARB). The CCB
could be another option if RAS is suspected. However,
an association of both drug classes is frequently
required.
All the other CV risk factors should also be managed
aggressively in parallel, as recently extrapolating the
demonstrated results in high cardiovascular risk hyper-
tensive patients included in the ASCOT trial (37).
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